Project Grant HT94252310995
Award Date
9/30/23
Completion Date
9/29/26
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This federal Project Grant award for $704,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Sloan-Kettering Institute for Cancer Research in New York, NY. The research aims to investigate the role of the NF-I/A transcription factor in regulating fatty acid metabolism in kidney cancer. This multi-year project will run from September 1, 2024 to August 31, 2028. As the prime grantee, the Sloan-Kettering...
This $176,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by the Sloan-Kettering Institute for Cancer Research to unravel the interactions of mitochondrially encoded complex I mutations with hypoxia and antitumor immune response in chromophobe renal cell carcinoma. The award period runs from September 1, 2025 to August 31, 2026. As a leading cancer research organization, Sloan-Kettering Institute...
The Defense Health Agency awarded a $619,500 Project Grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization in New York, NY. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program and will support research to investigate the immunogenicity and targeting of shared neoantigens in adenoid cystic cancer over a 3-year period from September 1, 2023 to August 31, 2026. The research aims to transform health care for Service...
The Sloan-Kettering Institute for Cancer Research was awarded a $707,346 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2024, supports Sloan-Kettering's cancer research initiatives, including investigations into the tumor microenvironment, mechanisms of metastasis, epigenetic alterations in cancer, resistance to cancer therapies, aging-related biology, and hematologic malignancies....
Sloan-Kettering Institute For Cancer Research was awarded a $796,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 15, 2023 through July 14, 2026. The grant will support research to develop novel tools to improve responses to DNA-damaging therapeutics in metastatic breast cancer. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise in cancer biology,...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $923,805.00 in funding to the Sloan-Kettering Institute for Cancer Research to conduct a systematic functional dissection of cancer cell states in lung tumors. The research aims to transform healthcare for military service members and the broader public through innovative and impactful cancer research. Key products and services to be delivered include...
This $176,000 Project Grant awarded by the Department of Defense (DOD) through the Military Medical Research and Development program (CFDA 12.420) supports research by the Sloan-Kettering Institute for Cancer Research to define the biology of and identify therapeutic vulnerabilities in DCK12-inactivated prostate cancer. The award period is from April 1, 2024 to March 31, 2025. As a non-profit organization focused on cancer research and patient care, Sloan-Kettering Institute has previously...
The Sloan-Kettering Institute for Cancer Research was awarded a $1,283,229 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from September 2021 through September 2025 to systematically characterize kidney cancer tumor suppressors and their role in modulating metastasis and response to immunotherapy. The Military Medical Research and Development program aims to transform military and public...
This $664,456 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research. The award will fund a 3-year research project focused on investigating biomarkers of immune response in mismatch repair-deficient (MMR-D) endometrial cancer treated with immune checkpoint blockade and radiation. The research aims to advance the understanding of cancer immunology and develop new...
The Sloan-Kettering Institute For Cancer Research was awarded a $1,062,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2025 to develop therapeutic activation of immunogenic cell death to improve immunotherapy for kidney cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research...